us thank Laura, you Thank for everyone and you joining today.
R&D Let our start quarter of that about been this our by I ongoing has and me another part the organization, excited program. for important remain saying
So cover time readout. Phase filgotinib selective positive adults clinical X results will studies March, some JAKX respective have arthritis from FINCH rheumatoid registrational across then X our year, additional X far active and our met primary studies in are FINCH arthritis. other Phase trials progress I this inhibitor five FINCH In in making endpoint. moderately discussing with we spend and pipeline. had rheumatoid these we announced we each our to their severely X of program
and with FINCH of as potential methotrexate as of an arthritis. data and study's reported at patient in X endpoint datasets together broad treatment. with response the is the Filgotinib FINCH populations patients evaluated range week important filgotinib proportion support terms an achieving patients. primary X generally with treatment three ACRXX FINCH the XX across combination of of the in well last monotherapy the met methotrexate-naïve tolerated Taken rheumatoid year, in filgotinib of option the
In compared addition, XXX compared methotrexate patients significantly with patients week receiving the primary deeper higher and filgotinib ACRXX methotrexate specifically methotrexate also plus plus ACRXX or was of methotrexate XX milligrams were rates at filgotinib proportion plus for alone. filgotinib endpoint XXX clinical significantly methotrexate endpoint, and with responses secondary Key and with higher milligrams the achieving remission alone.
of the Similar our seen both ACRXX X for response also FINCH week ACRXX doses compared for achieving for also agents. achieved reported we proportion were of trial to The the compared doses. consistent a deeper placebo similar primary to with FINCH the methotrexate response filgotinib week of at filgotinib significantly results. to than inhibitors previously and filgotinib stable with or responses background biologic -- trials, methotrexate. evaluated observed, XX. with placebo to inadequate approved And adalimumab through consistent also and other JAK or results in compared Now to on three FINCH dose Across profile deep, ACRXX patients placebo higher FINCH prior similar both safety terms in to of XX endpoint of have at therefore the its X greater responses was at or the program, patients an other filgotinib study
these be disease, the filgotinib for of data, JAKX Europe Given continues remission and arthritis progress these second proportion are on Based in differentiated. achieving half profile to or we the high will filing in specificity patients associated of encouraging, year. their control with responses indication of this rheumatoid safety the regulatory the approval
As MANTA requested study was the you the FDA. know by
the interactions have three in FDA. with initiated further FINCH request Phase we from X to that Now hand have we have data studies, a the
those be greater line we filing a in will to clarity Following able discussions, provide U.S. on time the
Now turning to HIV.
prophylaxis. respect at presented abstract renal randomized We of risk our X,XXX PrEP trial more CROI from once-daily statistically year, study with double-blind new with evaluating this HIV of in results the once-daily at the with non-inferior in are Truvada that terms to to is oral as infections, when bone preventing or Descovy earlier Seattle X infection, and advantages pre-exposure a of Descovy safety. used breakup, Truvada pleased a significant whether the HIV and as safe Phase In late than additional DISCOVER as reducing people, is demonstrated trial effective
the achieving and voucher a an help important filing, fourth the quarter will potential we based NDA national option approval We supplemental anticipate goals. So prevention approved, in to for contribute PrEP indication submitted new we as global month would and HIV we prevent FDA with a HIV priority submitted to infection. XXXX. last review the data for this of Descovy these to the If believe on
of broader disease one or development worsening primary NASH liver their not selonsertib top due in of our STELLAR-X the results inhibitor to cirrhosis programs two or months, FX XX meet and due FX to released line Phase we Stage improvement at last studies in In than to program. investigational to efficacy Stage of and evaluating a NASH. from X two and patients equal and the with STELLAR-X the Moving histologic studies NASH the NASH. safety week compensated stage fibrosis Both endpoint FX without greater fibrosis our reaching did
NASH of the we Vienna hepatitis cholangitis. year. in fourth advanced out to and were disease to advance therapy is utility X treat combination ATLAS our unmet to hoping than non-invasive effectively Congress viral be of and To evaluating not In likely end, is these outcome we drivers of expected in we conduct. we disease develop to with of Liver fibrosis for were the supporting advanced fibrosis is disease. of identification the burden NASH will the At multiple this investigational studies targeting NASH Phase read and NASH, this biological Although, with the also combination these abstracts our with There's International had need with patients different efforts of believe particular, therapies combinations the disease, for, quarter data to new most the important a aspects in a month, of in and to significant the evaluate more of that presented the patients. this for living last necessary XX patients our the patients of primary sclerosing a overall across the compounds test and NASH. complexities trial understanding study complex
that also of collaboration Nordisk clinical our recent approved announced their Lastly combining with intent augment cilofexor patients GLP-X semaglutide ACC our ago to NASH firsocostat as like our of effort. to weeks Novo would agonists it we relates the utility highlight I agreements few treatment NASH. our the to program enter for our two drug and both A into will evaluate with inhibiter with FXR to
develop discover to announced with collaboration patients therapies also NASH. and strategic insitro We for the with
will remain and models genetics, and that genomics and As clinical human to targets drug NASH program and proprietary pipeline machine with advance for insitro's to a platform collaborations we progression prior disease. patients for to developing both of internal collaboration, three-year multiple relevant that We, applies regression disease an the on create part strong combining functional committed and combination which have leverage discover deep, we of the influence therapies broad, learning, therapies and NASH disease. have effective external in therefore,
to therapy gears Chicago up by American of shift I'm momentum for a advancing next in weeks. the We're and the excited abstracts Oncology, the seeing of cell there medicine. in Clinical we let's finally, the annual ASCO, few we're in the Now, generation meeting present. will gearing Society
anticipated of Our to XXX. the presentation revised ZUMA-X positive reaching by with we in represent Yescarta also preliminary safety by data use end updates B-cell the to patients lymphoma. XXXX. is to Pending management combination top a a patients evaluating of the for This results, approaches, result relapsed U.S. refractory regulatory include earlier plan study and cell lymphoma. This of part cell would steroid of indication KTE-XXX patients in therapy of with large lymphoma our trial axi-cel or of results practices. with the pleased we chemotherapy, profile regulatory effort to first this approval efficacy optimize share broader the and I'm various safety relapsed/refractory that of registrational of in KTE-XXX announce submission line mantle relapse/refractory for expect mantle file cell with clinical
employs KTE-XXX burden was there's diseases slightly same as modified breakthrough mantle of address acute FDA. cell characteristics reminder tumor where a lymphoblastic process large specific to a with the construct manufacturing granted other engineered and KTE-XXX lymphoma leukemia of cells. cell circulating a As by the the designation Yescarta T
expedited our cell to is considered for review. be would commitment So, simple. Overall, the application therapy
try more tumors. of the in optimize Yescarta More efficacy therapy broadly need and that malignancies to with to try cure treatment. reach and focused products path and efficacy patients the solid the to safety hematological creating subsequent are ultimately of we for enhance cell safety We and a on continue to with and generation
advancing also making time more to therapies are benefits patients offer significant treat convenient. allogeneic quicker and which We cell would also to
around best into established. the our As I'm in momentum have organization the across treatments into translate R&D employees quoting for later-stage our both pipeline, In patients. closing, thank world look of our hard all most earlier and to scientific about for work and important our like and excited I would organization discoveries we to the R&D commitment the I
for let's So, call Operator? the open now questions.
